New Delhi: Hundreds of countries in the world are infected with Corona. More than 10 lakh 76 thousand people have died worldwide due to the devastation of Corona and more than 30 million 74 million people are suffering from covid-19 infection. Russia claims to have made the corona vaccine. Those expecting the corona vaccine have received another setback.
Vaccine trial on hold:
Johnson & Johnson has temporarily halted its clinical trial on Corona. In a statement issued on Monday by the company, it said that it has temporarily halted its trial due to an unexplained illness in a study participant.
Johnson & Johnson temporarily halted trials:
The company said that such temporary prohibitions continue in large trials, in which more than 10 thousand people are tried. A statement was issued by Johnson & Johnson stating, “We have temporarily halted the clinical trial of all our Covid-19 vaccines.” The company has attributed this to a participant being ill during research.
Johnson & Johnson’s move is similar to AstraZeneca plc. In September, Astrazeneca halted the trial of the last phase of its vaccine. AstraZeneca had stopped its trial due to an incomprehensible disease in a UK research. Although trials have resumed in the UK, Brazil, South Africa and India, trials have yet to begin in the US.
The vaccine dose produces immune response and has also been reported to be safe. So that human trials of vaccine candidates can be carried out on large groups. The company received considerable impetus after strong protection from Johnson & Johnson’s single dose on monkeys in July. It began preliminary-secondary human trials against Corona virus infection with the help of the US government.
Johnson & Johnson last month began the final phase of human trials at 60,000 people. The result of which is expected to come later this year or early 2021. Earlier reports claimed that Johnson & Johnson’s COVID-19 vaccine candidate found strong immune response against the corona virus.
Stay tuned with the newstrack to get fastest updates. Click to follow us on Facebook and to follow on twitter.
0 Comments